These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 11154233

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
    van Horssen PJ, van Oosterhout YV, Evers S, Backus HH, van Oijen MG, Bongaerts R, de Witte T, Preijers FW.
    Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
    [Abstract] [Full Text] [Related]

  • 24. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
    Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.
    Blood; 2003 May 01; 101(9):3641-7. PubMed ID: 12511412
    [Abstract] [Full Text] [Related]

  • 25. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
    Weber T, Mavratzas A, Kiesgen S, Haase S, Bötticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J.
    J Immunol Res; 2015 May 01; 2015():561814. PubMed ID: 26605343
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan 01; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 28. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL, Li JL, Vitetta ES.
    J Immunol; 1994 Mar 01; 152(5):2368-76. PubMed ID: 8133047
    [Abstract] [Full Text] [Related]

  • 34. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
    Rybak SM.
    Curr Pharm Biotechnol; 2008 Jun 01; 9(3):226-30. PubMed ID: 18673288
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
    Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, Hansen HJ.
    Mol Immunol; 1995 Dec 01; 32(17-18):1413-27. PubMed ID: 8643111
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.